Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... -- Lancée par l,Assistance Publique ... en décembre 2011, l,étude collaborative française randomisée et ...   l es microsphères en résine marquées ... carcinome hépatocellulaire avancé, a recruté plus de 400 ... ; les résultats sont attendus fin 2016.   ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... equipment, capable of generating intense pulses of light as short ... Red, will help scientists at the University of East Anglia ... and point the way to molecular structures for exploiting solar ... Engineering and Physical Sciences Research Council, the new laser will ...
... Feb. 28, 2012 Regado Biosciences, Inc., a privately held ... agents, announced that David J. Mazzo, PhD, President and CEO, ... Annual Health Care Conference at 1:30 p.m. EST on ... Boston, MA.  The presentation will include an ...
... NOVATO, Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical ... for rare and ultra-rare genetic disorders, today announced ... has granted orphan drug designation for UX003 for ... an extremely rare autosomal recessive lysosomal storage disorder ...
Cached Biology Technology:New laser can point the way to new energy harvesting 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 3Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... 2008Clinical researchers at Scottsdale Healthcare and TGen today announced ... for patients battling cancer. The Phase I ... Meeting of the American Association for Cancer Research by ... carcinoma (BCC) and pancreatic cancer. The Arizona trials were ...
... professor of molecular medicine Victor R. Ambros, PhD, ... world of investigation into developmental biology, will receive ... the most prestigious in science. Dr. Ambros shares ... of genetics at Harvard Medical School, with whom ...
... availability of new genome sequencing technology has prompted ... intriguing hypothesis about how agricultures early beginnings may ... Boris Vinatzer, assistant professor of plant pathology, physiology, ... and Life Sciences, has received a $1 million, ...
Cached Biology News:2 new therapies show promise for cancer patients 22 new therapies show promise for cancer patients 3UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 2UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 3Tomato pathogen genome may offer clues about bacterial evolution 2
Request Info...
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
... The ULS cDNA Synthesis and Labeling ... microarray hybridization experiments. First unmodified cDNA is ... into cDNA using an Oligo(dT) primer. Unlike ... nucleotides used in the reverse transcription reaction. ...
... that enables fully automated hybridization of microarrays ... has been designed to offer researchers improved ... to perform a wide range of applications. ... range 485C; denaturations of up to 99C. ...
Biology Products: